StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Earnings

Sangamo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2026
$1.40M
EPS, Q1 FY2026
-$0.08
Latest guidance
Issued
May 14, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Sangamo Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close$1.40M–-$0.08Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026after the close$14.20M+86.8%-$0.11Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$600.00K-98.8%-$0.11Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$18.30M+6000.0%-$0.08Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025after the close$7.60M–-$0.11Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024after the close$49.40M–$0.04Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$300.00K–-$0.18Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$500.00K–-$0.27Release
Q4 FY2023ended Dec 31, 2023Mar 13, 2024before the open–––Release
Q3 FY2023ended Sep 30, 2023Nov 1, 2023after the close–––Release
Q2 FY2023ended Jun 30, 2023Aug 8, 2023after the close–––Release
Q1 FY2023ended Mar 31, 2023Apr 26, 2023after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Sangamo Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
non-GAAP total operating expensesnon-GAAPFY2026$100.00M – $120.00M–NewMay 14, 2026
total operating expensesGAAPFY2026$110.00M – $130.00M–NewMay 14, 2026
non-GAAP total operating expensesnon-GAAPFY2026$110.00M – $120.00M–NewMar 30, 2026
total operating expensesGAAPFY2026$120.00M – $140.00M–NewMar 30, 2026

Guidance history

Every forecast Sangamo Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 14, 2026non-GAAP total operating expensesFY2026$100.00M – $120.00MNew
May 14, 2026total operating expensesFY2026$110.00M – $130.00MNew
Mar 30, 2026non-GAAP total operating expensesFY2026$110.00M – $120.00MNew
Mar 30, 2026total operating expensesFY2026$120.00M – $140.00MNew
Nov 6, 2025non-GAAP total operating expensesFY2025$125.00M – $145.00MReaffirmed
Nov 6, 2025total operating expensesFY2025$135.00M – $155.00MReaffirmed
Aug 7, 2025non-GAAP total operating expensesFY2025$125.00M – $145.00MNew
Aug 7, 2025total operating expensesFY2025$135.00M – $155.00MNew
Mar 17, 2025non-GAAP total operating expensesFY2025$125.00M – $145.00MNew
Mar 17, 2025total operating expensesFY2025$135.00M – $155.00MNew
Nov 12, 2024non-GAAP total operating expensesFY2024$125.00M – $145.00MReaffirmed
Nov 12, 2024total operating expensesFY2024$150.00M – $170.00MReaffirmed
Aug 6, 2024non-GAAP total operating expensesFY2024$125.00M – $145.00MNew
Aug 6, 2024total operating expensesFY2024$150.00M – $170.00MNew
May 9, 2024non-GAAP total operating expensesFY2024$125.00M – $145.00MNew
May 9, 2024total operating expensesFY2024$145.00M – $165.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Sangamo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Update
  5. Update
  6. News
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?